Painful Diabetic Neuropathy in Advanced CKD With Orthostasis
72-year-old woman (58 kg) with painful diabetic peripheral neuropathy describes 7/10 burning in both feet for 1 year. eGFR has been 26–30 mL/min/1.73 m² for 6 months; HbA1c 8.9%. Medications: metformin, lisinopril, furosemide, atorvastatin. Gabapentin 300 mg at bedtime caused sedation and unsteadiness, and she stopped after three doses. Supine BP is 102/60 mm Hg and standing BP 88/54 mm Hg. She lives alone, drives, and asks for “something stronger,” having heard duloxetine helps nerve pain. She has no history of depression, falls, or alcohol use. Examination shows reduced vibration and pinprick in a stocking distribution, absent ankle reflexes, and no foot ulcers.
1. Select the most appropriate next pharmacologic step for her neuropathic pain, including drug, starting dose, titration, and monitoring. Explain why the obvious alternatives are less suitable.
Read the worked answer
At an eGFR of 26–30, duloxetine is not recommended because severe renal impairment increases exposure and adverse effects; she also has orthostatic hypotension and hyponatremia risk, both worsened by duloxetine. Amitriptyline is a poor choice given orthostasis, anticholinergic burden, and fall risk. Tramadol should be avoided because of renal impairment, hypoglycemia risk, and seizure/serotonergic concerns. A reasonable step is a low-dose gabapentinoid: pregabalin 25 mg at bedtime or gabapentin 100 mg at bedtime, with slow titration every 3–7 days to effect and tolerance. Counsel on sedation, dizziness, edema, and falls; check renal function at baseline and after dose changes. Add topical lidocaine 5% patches to the feet for up to 12 hours daily as a systemic-sparing adjunct. Opioids are not first-line.
2. What nonpharmacologic, safety, and self-management measures would you build into the plan, and how would you counsel her about driving?
Read the worked answer
Address modifiable contributors: glucose control, foot care, and sleep. Refer for pain self-management/CBT and a structured walking or aquatic program that respects her orthostasis. Review home safety and fall prevention because she lives alone; recommend rising slowly and avoiding nighttime sedatives. For driving, advise that she should not drive if she feels sedated or unsteady, especially during titration; she should trial the new medicine on a non-driving day and have a passenger or alternative transport initially. Reassess orthostatic vital signs and sedation at each visit. Set functional goals such as standing tolerance, sleep continuity, and walking distance rather than pain score alone. Coordinate with primary care about metformin dosing at her eGFR and about BP targets.
3. Two months later her eGFR falls to 18 mL/min/1.73 m². How does that change your medication plan?
Read the worked answer
At eGFR 18, both gabapentin and pregabalin require substantial dose reduction and may accumulate, causing sedation, myoclonus, and falls; many clinicians would stop the gabapentinoid or use the lowest intermittent dose rather than continue titrating. Duloxetine remains inappropriate. Topical lidocaine can continue if the skin is intact, and nonpharmacologic modalities become more important. Review all renally cleared drugs with primary care and avoid NSAIDs and tramadol. If pain remains disabling, refer to a pain specialist or palliative care clinician experienced in advanced kidney disease rather than adding an opioid casually. Reassess goals and safety, and document shared decision-making.